7 Links Between Menopause and Hidradenitis Suppurativa That Explain Why Flares Worsen in Midlife
The number of women who write in saying their HS 'suddenly got out of control' in their mid-forties is striking — and heartbreaking, because almost none of them had been told hormones could be the trigger. Getting this piece of the puzzle earlier changes everything about how you approach treatment and how kindly you treat yourself on the hard days.
Learn more about Rose →Falling Estrogen Removes a Natural Anti-Inflammatory Shield
Estrogen has well-documented immunomodulatory properties, helping to regulate the inflammatory cytokines — including TNF-α and IL-1β — that are chronically elevated in HS tissue. As estrogen declines through perimenopause, this regulatory brake weakens, allowing inflammatory pathways that drive HS lesion formation to run with less opposition. This is one reason why the condition that felt manageable at 38 can feel relentless by 48.
Androgen Dominance Becomes More Pronounced as Estrogen Falls
HS has a known androgen-sensitive component — the apocrine and follicular glands most affected by the disease express androgen receptors, and excess androgenic activity promotes the follicular occlusion that initiates HS lesions. When estrogen drops during perimenopause, the relative ratio of androgens to estrogen shifts, even if total androgen levels aren't dramatically elevated. This relative androgen dominance can be enough to push a previously stable condition into more frequent and severe flaring.
Chronic Low-Grade Inflammation Is a Hallmark of Both Conditions
Menopause itself is associated with a measurable rise in systemic inflammatory markers, including C-reactive protein and interleukin-6, driven partly by the loss of estrogen's anti-inflammatory effects and partly by metabolic changes in midlife. HS is already a disease of dysregulated innate immunity and chronic inflammation, so adding a whole-body pro-inflammatory state effectively pours fuel on an existing fire. Women with HS entering menopause are essentially managing two overlapping inflammatory conditions simultaneously.
Disrupted Sleep Impairs Skin Immune Regulation
Sleep disruption is one of the most common and underappreciated symptoms of perimenopause, driven by night sweats, anxiety, and altered circadian signaling as hormones shift. Poor sleep is independently linked to upregulation of pro-inflammatory cytokines and impaired skin barrier function, both of which are relevant to HS disease activity. Research into inflammatory skin conditions broadly shows that sleep deprivation can trigger or worsen flares, and HS is particularly sensitive to immune dysregulation of this kind.
Weight Gain Around the Abdomen Raises Inflammatory Load
The hormonal shifts of menopause — particularly declining estrogen and rising cortisol reactivity — promote fat redistribution toward visceral adipose tissue, which is metabolically active and secretes pro-inflammatory adipokines like leptin and resistin. HS is strongly associated with obesity and metabolic syndrome, partly because adipose tissue amplifies the inflammatory environment that sustains the condition. Even modest midlife weight gain in the abdominal region can measurably worsen the inflammatory backdrop against which HS operates.
Cortisol Dysregulation Adds a Stress-Inflammatory Loop
The hormonal turbulence of perimenopause alters the HPA axis, making the stress-cortisol response less well-regulated and more reactive. Elevated or erratic cortisol suppresses adaptive immunity while simultaneously promoting the innate inflammatory pathways that are already overactive in HS, creating a feedback loop where stress worsens flares and painful flares increase stress. Women navigating midlife pressures alongside HS often describe their skin worsening during emotionally demanding periods — this is the physiological mechanism behind that pattern.
Hormonal Therapy May Offer a Meaningful Adjunct — But the Evidence Is Still Developing
There is emerging clinical interest in whether hormone replacement therapy — particularly combined estrogen-progestogen or anti-androgenic preparations — might help reduce HS flare frequency in perimenopausal women by restoring some of the hormonal balance that modulates the condition. Small studies and case reports suggest benefit in some women, particularly those whose flares clearly correlate with hormonal events like menstruation or menopause onset, though large randomised controlled trials are lacking. This is an important conversation for women with HS to have with both their dermatologist and their menopause specialist, as treatment decisions need to account for their full hormonal picture.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.